netupitant palonosetron (Akynzeo) -

netupitant palonosetron (Akynzeo)
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Cancers | Gastrointestinal disorders
Summary
The SMC has accepted restricted use of netupitant/palonosetron within NHS Scotland, for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in adults.
UKMi comment
This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Related links: